Abstract
Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Current Opinion in Molecular Therapeutics |
| Vol/bind | 7 |
| Udgave nummer | 6 |
| Sider (fra-til) | 604-10 |
| Antal sider | 7 |
| ISSN | 1464-8431 |
| Status | Udgivet - dec. 2005 |
| Udgivet eksternt | Ja |